Tom Blount

Tom Blount

SVP, President, North America

Tom Blount serves as the SVP, President, North America of embecta. Previously, Tom spent 6 years with BD, as VP/GM US region Diabetes Care, WW VP/GM Infusion and Global Marketing leader for Diabetes Care and additional upstream marketing roles. Prior to BD, Tom spent the last 16 years at Sanofi in various roles including Associate VP of Diabetes Value and Access, Associate VP of Toujeo Value & Access, Associate VP Lixisenatide Family Marketing, Sr. Director of Marketing Strategy for Sanofi Genzyme R&D, Sr. Director of Marketing Strategy for the Fibrosis Wound Repair Global Strategy Unit, Director of General Therapeutics Mature Brands, Director & Commercial Alliance Leader for XYZAL Marketing, and many other roles in Sales and Marketing.

Tom has vast launch experience in a variety of sales, marketing and market access roles and in a variety of disease areas including diabetes. Tom also spent 5 years on active duty finishing as a Captain in the United States Army. He holds a Bachelor of Science degree in German/French from the United States Military Academy at West Point and a Master of Science in International Relations from Troy University – European Campus.

    Forward Looking Statement

    The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

    All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.